ProofPilot to Integrate Lilly's Magnol.AI™ Sensor Cloud Into its Clinical Trial Automation Platform
ProofPilot has announced a strategic collaboration with Eli Lilly and Company (Lilly) to offer Lilly's patent-pending, sensor cloud platform, Magnol.AI™, a platform that enables management of high-frequency sensor data with security, as part of ProofPilot's technology solution.
For the first time, Lilly is out-licensing its technology. This technology-focused collaboration with Lilly and ProofPilot will enable both companies to help the broader research community to execute digital health research, helping to accelerate pre-competitive biomedical research.
"We are thrilled to collaborate with Lilly and leverage its industry-leading sensor cloud, further strengthening our commitment to provide our customers with the most advanced solutions and enable flawless execution of clinical research" said Chris Venezia, CEO of ProofPilot in a press release. "By integrating Magnol.AI™ into our platform, researchers finally have a one-stop, comprehensive solution to execute digital health research and deliver sensor data-driven insight with the highest quality."
Magnol.AI™ is Lilly's sensor cloud platform that allows for ingestion, visualization, and extraction of high-frequency sensor data with security. It is able to ingest and align a wide array of raw data from wearables, devices, and beyond in a clear time-series format. When aligned with clinician and patient reported outcomes, Magnol.AI™ enables real-time data science capabilities for digital health and digital biomarker research.
ProofPilot's mission is to perfect clinical research execution by orchestrating technology, tasks, content, and communication through its clinical trial automation platform. When combined with Lilly's sensor cloud Magnol.AI™, ProofPilot delivers a data science solution to digital health and digital biomarker researchers around the world. With this new integration, any researcher can now have access to a digital health research platform that combines data collection, sensor ingestion, device management, and participant engagement.
Reference
ProofPilot To Integrate Lilly's Magnol.AI™ Sensor Cloud Into Its Clinical Trial Automation Platform. (2023, September 28). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
